Monica Smith

Early-stage colorectal cancer patients may benefit from a new test that predicts their risk of recurrence.

The FDA decides to wait on reviewing Prolia (denosumab) for reducing treatment-related bone loss in breast and prostate cancer patients, but a new study may shed light on the drug’s importance.